Global Leadership Shake-up in MedTech: Executive Moves at Medtronic, Johnson & Johnson, Mindray and 24 Other Firms

Mar 05, 2024 00:01 CST Updated 00:01

Medtronic

Chronic Disease Medical Device and Therapy Developer

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

GE Healthcare

Digital Solution Provider

Philips

Healthcare Service Provider

Intuitive

Surgical Robot Developer

Boston Scientific

Medical Device Manufacturer

Abbott

Diagnostic and pharmaceutical product manufacturers

Zimmer Biomet

Medical Device R&D Manufacturer

BD

Medical Device R&D Manufacturer, Distributor

LivaNova

Medical Device Supplier

Mindray

Medical Device R&D Manufacturer

Baxter

Disease Treatment Product Developer

Insulet

Medical Device Supplier

ResMed

Medical Device + Cloud-Based Software Solution Provider

ReCor Medical

Developer of Renal Denervation Devices

Silk Road Medical

Minimally Invasive Medical Device Developer

Cordis

Medical Device Manufacturer

ORTHOFIX

Orthopedic Medical Device Developer

Distalmotion

Surgical Robot Developer

Shockwave Medical

Cardiovascular Disease Treatment Device Developer

Biosense Webster

Developer of Diagnostic and Therapeutic Devices for Arrhythmia

Dexcom

Blood Glucose Monitoring System Developer

iRhythm

Innovative Diagnostic Monitoring Solutions Technology Provider

Integra LifeSciences

Comprehensive Medical Equipment Company

Source of the article:Instrument Workplace;Editor:Yang Liurong

Please be sure to indicate the source of the article at the beginning of the text. Thank you.！

With the rapid development of the global medical device industry, personnel changes in medical device companies often imply adjustments in corporate strategic intent and market positioning, which can have significant and far-reaching impacts on the entire medical device industry.Medical Device Workplace has compiled a list of executives from 27 global medical device companies in 2023.Promotions, resignations, dismissals, and other personnel changes。

# 01 Medtronic

Medtronic, the global medical device giant, experienced a series of executive leadership changes in 2023. In January, Medtronic appointed a former senior executive from Danaher who had served there for a long time.Scott CandyForSenior Vice President and Chief Quality Officer。Scott Candy MainResponsible for overseeing Medtronic's global quality. Additionally,Scott CandyIs a member of the Medtronic Executive Committee.

Medtronic's appointment this time is mainly to address the situation at the time.HeartWare Ventricular Assist DeviceThe issues include being classified as a Class I recall by the FDA and receiving a warning letter from the FDA regarding the diabetes business.This appointment also marks a return for Scott Candy.Scott Candy has been withMedtronic has worked for 10 and a half years, holding various quality, regulatory, and clinical leadership roles in the cardiac and arrhythmia management business fields.

Medtronic CEO Jeff Martha said, "Scott Candy's strong background in product quality, engineering, and regulation, along with his extensive executive experience and meticulous operational capabilities, will enable us to continue critical and impactful work in safety and quality functions."

Before returning to Medtronic,Scott CandyWorked at Danaher for nearly 13 years. Before leaving,Scott Candy holds the position of Vice President for Quality, Regulatory, and Clinical Affairs for Diagnostic and Life Science Platforms at Danaher.Responsible for developing strategies to meet global regulatory and compliance requirements.

In March, MedtronicPresident of the Surgical Robotics DivisionMike MarinaroPromoted toExecutive Vice President and President of the Surgical Department,Responsible for overseeing a comprehensive, market-leading surgical product portfolio and integrating traditional surgical equipment with new robotic-assisted surgical technologies to redefine the future of surgery. (For more details, see "Medtronic Responds! Official Announcement of Surgical Robotics Business Adjustment》）

Medtronic did not issue a press release to announce this executive promotion, but only updated its official website, indirectly confirming Mike Marinaro.The new title and the "newly merged" Department of Surgery. But in factIt is the first move in Medtronic's restructuring, and also indicates that Medtronic is seeking to merge its business units to cut company expenses.

Mike Marinaro joined Medtronic in 2000 and has more than 20 years of management experience.Mike MarinaroZengLed teams for tachycardia, bradycardia, and infection control to bring implantable device products to market – from innovation to launch and achieving market success.Mike Marinaro has alsoServed as the president of the Cardiac Rhythm Management Operations for four years, leading the acquisition of the Micra™ Transcatheter Pacing System and the TYRX™ franchise, and successfully expanding Medtronic's business in China.

In June, Medtronic appointed a former Amazon executive.Ken WashingtonForSenior Vice President and Chief Technology & Innovation Officer。Ken Washington MainResponsible for accelerating Medtronic's innovation through product development and technology strategy. Meanwhile, he also becameMember of the Medtronic Executive Committee.

Medtronic CEO Jeff Martha said: "Ken WashingtonThis will help Medtronic carry forward the innovative spirit of its founders and ensure that Medtronic uses technological inventions to create future medical technology scenarios.”

Ken Washington's Previous JobAs Vice President and General Manager of Amazon's consumer robotics, he previously served as Chief Technology Officer at Ford Motor Company, overseeing the development of the company’s technology strategy, including next-generation vehicle architecture, controls, and automation systems.He also worked at Lockheed Martin for seven years, holding various leadership positions, including Chief Technology Officer, Chief Privacy Officer, and Vice President of the Advanced Technology Center at Lockheed Martin Space Systems.

Ken WashingtonJoining Medtronic brings deep expertise in the development and execution of leading technologies from industries such as robotics, consumer goods, automotive, and aerospace.Ken Washington will help Medtronic expand the use of technology platforms across its product portfolio, including robotics, sensors, implants, and artificial intelligence.Thereby enhancing Medtronic's return on investment in innovation, expanding Medtronic's technological competitive advantage, and driving sustained growth.

In October, Medtronic appointed a former executive of Smith & Nephew.Paul DivincenzoForPresident of Neuromodulation BusinessPaul DiVincenzo served as Senior Vice President and General Manager of Advanced Wound Management at Smith & Nephew in the United States. During his nine years at Smith & Nephew, he also held global marketing and leadership roles. (For more details, see "Just Now! Medtronic Officially Announces President of This Business》）

According to器械职场, Medtronic's neuromodulation and pelvic floor health business includes a variety of innovative minimally invasive surgical therapies such as deep brain stimulation, spinal cord stimulation, intrathecal drug delivery systems, sacral neuromodulation, and spinal intervention.Brett Wall, Executive Vice President of Medtronic and President of the Neuroscience Portfolio, said: "As neuromodulation enters the era of personalized medicine with the adoption of sensing technology, I am thrilled.The addition of Paolo Di Vincenzo.HeIn line with Medtronic's performance-driven corporate culture, it will play a key role in advancing Medtronic's efforts in the field of neuromodulation and drive business implementation.”

In 2023,Personnel Changes in Medtronic's Senior Management,In addition to the appointments and promotions mentioned above, it also includes voluntary resignation.According to reports from the medical device industry, the executives who have left Medtronic includeExecutive Vice President and Chief Human Resources Officer Carol Safford,Julie Brewer, President of Cardiovascular Diagnostics and Services,Vice President and General Manager of the Spine and Biologics Division, etc.

# 02 Johnson & Johnson

Johnson & Johnson is one of the most comprehensive medical and health product enterprises with a wide range of business distribution globally. Johnson & Johnson Medical Technologies, the medical device business segment under Johnson & Johnson, entered the Chinese market in 1994. In the first half of 2023, several senior management personnel changes occurred at Johnson & Johnson Medical Technologies China. In the second half of 2023,The leader of Johnson & Johnson's global medical technology business has also changed.

On March 3, Johnson & Johnson China announced internally,Chen Xi, General Manager of Johnson & Johnson Medical Technology China Cardiovascular and Professional Solutions Division、Johnson & Johnson Medical TechnologiesChen Min, General Manager of China Orthopedics DivisionHas submitted a resignation to the company, deciding to seek external development opportunities. Meanwhile, an appointmentVice President of Spine and PCMFT Division, Han WeiSucceeding Chen Min, becomingNewly AppointedJohnson & Johnson Medical TechnologiesGeneral Manager of Orthopedics in China.

Chen Xi joined Johnson & Johnson Medical Technologies China in 2018 as the head of the Electrophysiology Division. Starting from January 2020, he served as the General Manager of the Cardiovascular and Specialty Solutions Division (CSS) in China and acted as the rotating chair of the Johnson & Johnson China DEI Committee. On March 31, 2023, Chen Xi officially left Johnson & Johnson Medical Technologies China, where he had worked for five years. (For the latest updates on Dr. Chen Xi, please see "Former General Manager of Johnson & Johnson Medical Announces Next Move!》）

Chen Min is a 15-year "veteran" of Johnson & Johnson. She joined Johnson & Johnson Medical Technologies China in 2007 and has held several key positions in surgery and orthopedics, including Head of Trauma Business, Senior Director of the Energy Platform Division, and Head of Ethicon Biosurgery. In January 2018, she became the General Manager of the Orthopedics Division.

Han Wei joined Johnson & Johnson Medical Technologies China through campus recruitment. He started as a frontline salesperson, later serving as the Director of the Cordis Endovascular and ASP divisions. From 2016 to 2018, he participated in the global development program (IDP) in the United States, where he served as the Director of BW's Global Strategic Marketing Department. In March 2018, Han Wei returned to China to take on new challenges, successively leading Johnson & Johnson Medical Technologies China’s Innovation Team and Strategic Customer Team. In January 2021, Han Wei was transferred.Johnson & Johnson Medical Technologies ChinaServed as the Senior Director of the Joint Division in the Orthopedics Department, and in November of the same year, transferred to the Spine and PCMFT Division to serve as Vice President.

On April 12, Wang Jinhe, Vice President of Operations and Professional Education at Johnson & Johnson Medical Technology China, submitted his resignation to the company, deciding to pursue external development opportunities.

Wang Jinhe is aJohnson & Johnson's 20-year "Veteran". He is inFrom June 2003 to April 2023, he successively held positions such as Sales Manager, Product Manager, Marketing Manager of Ethicon Wound Closure at Johnson & Johnson Medical (China), Director of Ethicon Biosurgery, Senior Director of the Electrophysiology Division (BW), General Manager of the Cardiovascular & Specialty Solutions Group (CSS), Vice President of Market Access & External Affairs, and Vice President of Operations & Education. (For more information on Mr. Jinhe Wang, see "Johnson & Johnson, Another Senior Executive Departs!"》and《"Latest Official Announcement! Vice President of Johnson & Johnson China Joins Listed Company》）

October,Johnson & JohnsonExecutive Vice President and Global Chairman of the Medical Technology DivisionAshley McEvoy announced her resignation, and her successor is Tim Schmid, who was the chairman of Johnson & Johnson's Asia-Pacific Medical Technology Company (APAC) at the time.. (For details, see "Johnson & Johnson: Executive Departure! Medical Technology Leadership Change》）

Ashley McVoyShe joined Johnson & Johnson in 1996 and spent the first 10 years of her career in the consumer health sector, including serving as the president of what was then called McNeil Consumer Healthcare.Ashley McVoyIn 2009, he was transferred to Johnson & Johnson's medical device division to serve as the global president of Ethicon, a subsidiary of Johnson & Johnson's surgical technology branch. Subsequently, in early 2012, he was appointed as the chairman of the Vision and Diabetes Care Group.She took the helm of Johnson & Johnson's medical technology business in June 2018. In 2022,Ashley McEvoy, with an annual salary of nearly $7.4 million, has been included in Johnson & Johnson's disclosed list of the highest-paid executives.

During nearly three decades of career at Johnson & Johnson,Ashley McEvoy is most commendable for leading Johnson & Johnson's $27 billion medical device division, the world's second-largest medical device business, and achieving many accomplishments.This includes leading the development of integrated digital solutions to improve the health of millions of people worldwide, guiding Johnson & Johnson into the fields of telemedicine, robotics, and digital surgery, as well as deploying over $20 billion in mergers and acquisitions in recent years to expand the company’s portfolio.

Tim Schmid joined Johnson & Johnson in 1993, initially serving in the role of "Strategic Customer and Professional Sales" at LifeScan (the blood glucose monitoring business that Johnson & Johnson divested in 2018). Prior to the divestiture of this business,Tim SchmidAt LifeScan, he was continuously promoted, becoming the Director of Acquisitions and Integration in 2001, then the General Manager of the UK and Ireland regional business in 2003, and later serving as the Vice President of the Europe, Middle East, and Asia region in 2006. In 2009,Tim SchmidBecame the Global Strategic Marketing Vice President of Johnson & Johnson's Ethicon division and was promoted to President in 2012.

Thereafter,Tim SchmidBecame the Chief Strategic Customer Officer of Johnson & Johnson Medical Technologies.In his role, he led the transformative change in Johnson & Johnson's business-to-business relationships with the U.S. healthcare system.Tim SchmidBegan serving as the Chairman of Johnson & Johnson Medical Technology Asia-Pacific in 2018 and led the Asia-Pacific business to achieve growth higher than Johnson & Johnson's global market.

# 03 GE Healthcare

On January 4, 2023, GE Healthcare was spun off from GE Group and listed as an independent company on the Nasdaq Stock Exchange. After GE Healthcare's independent listing, two significant personnel appointments were announced.

On January 5, GE Healthcare announced the appointment of a former Amazon executive.Dr. Taha Kas-HoutForThe First Chief Technology Officer。Dr. Taha Kas-HoutReport to the President and CEO of GE Healthcare, and collaborate with GE Healthcare's four business units (Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics) as well as engineering and machine learning (ML) teams across different regions.

Dr. Taha Kas-HoutA leader in the field of health informatics and analytics for two decades. As a physician and bioinformatician, he served as the FDA's first Chief Health Informatics Officer, leading innovations such as openFDA and precisionFDA, and was an advocate for the FDA's cross-cutting regulatory science initiatives.

Before joining GE Healthcare,Dr. Taha Kas-HoutFormerly served as Vice President of Machine Learning at Amazon Web Services and Chief Medical Officer of Amazon Web Services, establishing and leading the Health AI strategy and technology.Moreover, under his leadership, Amazon established Amazon HealthLake, Amazon Comprehend Medical, and Amazon Omics for industries such as healthcare, genomics, and life sciences, providing medical institutions with mature and easy-to-use functions to help businesses accelerate innovation and unlock the potential of health data.

On May 9, GE Healthcare announced the appointmentFormer Chief Financial Officer of Baxter International, Inc.Jay Sacaro, forSenior Vice President and Chief Financial Officer。Jay Sacaro joined Baxter Healthcare in 2002 as the strategic manager of its bioscience business unit.Jay Sacaro worked at Baxter for 21 years,Among them, he served as the Chief Financial Officer of Baxter Healthcare for 8 years. (For details, see "Executive Job-Hopping! From Dialysis Giant to GE Healthcare》）

# 04 Philips

On March 14, 2023, Philips announced the appointmentJulia StrandbergForExecutive Vice President and Chief Business Leader of the Connected Care Business UnitThe previous head of the department, Roy Jacobs, officially advanced to become Philips' Chief Executive Officer and President on October 15, 2022.

Philips' Connected Care business segment mainly focuses on sleep and respiratory care, patient monitoring, and informatics products. According to the device market,Philips Appoints New Executive to Handle FDA-Ordered Recall of Ventilators. This recall incidentStarting in June 2021, more than 5.5 million recalled ventilators have been involved. This recall event has kept Philips under pressure for over a year.Sleep Apnea MarketExclude. While its competitor ResMed's market share has been continuously growing.

# 05 Intuitive Medical

On May 16, 2023, Intuitive Surgical, the leading company in the surgical robotics field, announced significant changes in its senior leadership to support its global expansion strategy. (For details, see "Da Vinci Firmly Advances Globalization! Major Personnel Adjustments》）

Former Executive Vice President and Chief Strategy and Growth Officer of Intuitive SurgicalDave RosaPromotionPresidentOne position, responsible for leading Intuitive Surgical's product, digital, quality, regulatory, supply chain, manufacturing, and commercial teams.

Previously held the position of PresidentDr. Gary S. GuthartContinue to serve as the company'sChief Executive Officer and Board MemberResponsible for market positioning, strategic planning, departmental governance, corporate culture, as well as business incubation and product innovation in the early stages.

Bob DesantisFor newExecutive Vice President and Chief Strategy and Corporate Operations Officer。

Dave RosaIs a senior expert and leader in the field of robot-assisted surgery, joined Intuitive Surgical in 1996, and has been with the company for 27 years as a senior employee. Currently serves as the President of Intuitive Surgical, Inc.Dave RosaHeld key leadership positions in product, digital, quality, regulatory, supply chain, manufacturing, commercial, engineering, clinical development, marketing, and product development at Intuitive Surgical, most recently serving as Executive Vice President and Chief Strategy & Growth Officer. After being promoted to President,Dave RosaWill be responsible for leading Intuitive Surgical's core business, driving the digitalization and commercialization of products, and achieving the company's global expansion goals.

Dr. Gary S. GuthartJoined Intuitive Surgical in 1996 and has held key leadership positions in the company's engineering, clinical development, marketing, and product development departments. He became CEO in 2010 and has continued to serve in this position to this day.

Before joining Intuitive Surgical, Inc.,Dr. Gary S. GuthartHe once participated in the development of foundational technologies for computer-assisted surgery at SRI International (formerly Stanford Research Institute). He also conducted scientific research on pilot human performance evaluation at NASA's Human Factors Laboratory.In addition,Dr. Gary S. GuthartAlso a member of the board of directors of Illumina and the Silicon Valley Leadership Group.

In this personnel change, Intuitive Surgical also established a new position of Executive Vice President and Chief Strategy and Corporate Operations Officer, to be held byBob DesantisServe as.Bob DesantisHaving worked at Intuitive Surgical for 10 years, he previously served as Executive Vice President and Chief Product Officer. He will be responsible for strategic planning, operational structure, and management.

# 06 Boston Scientific

On February 13, 2023, cardiovascular giant Boston Scientific Corporation promoted from within.Kenneth StanPh.D.Senior Vice President and Global Chief Medical Officer.Dr. Kenneth Stein primarily oversees rhythm management, clinical trials, medical safety, and medical affairs functions for the Global Clinical Operations (GCO) team and the Global Medical Affairs team, and is responsible for ensuring cohesion across the company’s clinical practice teams.

Dr. Kenneth StanJoined Boston Scientific in 2009 as Senior Vice President and Chief Medical Officer of its Rhythm Management business.Before joining Boston Scientific,Dr. Kenneth StenHe served as the Deputy Chief of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and as an Associate Professor of Medicine at Cornell University. He has a particular focus on cardiac resynchronization therapy and risk stratification for cardiac arrest, and has published more than 150 papers in this field.

# 07 Abbott

In 2023, both the headquarters of Abbott and the leadership of Abbott China underwent significant adjustments.The executive team restructuring at Abbott's headquarters involves positions including Chief Financial Officer, Executive Vice President of Finance, and、Chief Financial Officer, etc.The position of General Manager of Abbott Electrophysiology in China has also undergone adjustments.

Philippe Boudreau, the newly appointed Senior Vice President of Finance and Chief Financial Officer of Abbott, officially assumed office on September 1, 2023. This is Abbott's headquarters'...Positions, respectively, in 2017、Another change after the changes in 2020。

Apart from simple job rotation

，

Abbott's headquarters also made adjustments to the leadership structure responsible for finance.

。

Reorganization details are as follows

：

Promotion OriginVice President and Chief Financial OfficerPhilippe Boudreau, forSenior Vice President and Chief Financial Officer;
Promotion OriginChief Financial OfficerBob Fink, forExecutive Vice President of Finance;
Promotion OriginAbbott Financial ControllerJohn McCoy Jr.CFO.

In addition, according to an internal announcement by Abbott Medical

，

Liu Bei, former Senior Director of Edwards China's Valve Therapy Business Unit, assumed the position on July 20, 2023.General Manager of Abbott Electrophysiology China

。

At the same time，Former General Manager of Abbott Electrophysiology ChinaChen LanAsSenior Director of Business Development, Asia-Pacific Region，Continue to focus on many key strategic initiatives in China and the Asia-Pacific region，And closely cooperate and hand over with Liu Bei.，Addressing a series of challenges such as VBP。

# 08 Zimmer Biomet

In August 2023, Zimmer Biomet,President and Chief Executive OfficerBrian Hanson, announced resignation,Turn toLead 3M's Health Care Division。The business of this healthcare division includes wound care, health IT, and biopharmaceutical filtration. In 2022, the sales of this healthcare division reached $8.4 billion. 3M hopes to complete the spin-off by the end of 2023 or early 2024. (For details, see "Latest! Orthopedic Giant Announces Leadership Change》）

Brian HansenSince 2017, served asZimmer BiometPresident and Chief Executive Officer. HeLed the company to turn losses into profits and presided over the divestiture of the spine and dental businesses. Prior to this, he led Medtronic's Minimally Invasive Therapies Group.

Brian Hansen's departure triggered a chain reaction.Zimmer Biomet Promotes Chief Operating OfficerIvan TornosForPresident and Chief Executive Officer, and implement other leadership adjustments. At the same time, 3M hired the former Chief Financial Officer of InsuletWade McMillan,Responsible for the financial operations of the healthcare department; former president of 3M Healthcare Division, Jim Lavers, has left.Brian Hansen.

# 09 BD

In June 2023, BD Medical was promoted.Brooke StoryForPresident of the Surgical Business Unit。Brooke Story is responsible for driving the global strategy, operations, and commercial performance of the Surgical Business Unit and reports to the Executive Vice President and President of the Interventional Division.

Brooke StoryJoined BD in 2021,Former President of the Integrated Diagnostic Solutions division.Prior to this, she worked at Medtronic for 15 years, serving as a leader in the Pelvic Health and Gastric Therapies business areas.Provide patients with life-restoring solutions for pelvic floor disorders.

# 10 LivaNova

In April 2023, Damian McDonald, CEO of ECMO giant LivaNovaAnnounced resignation. William Cozzi, Chairman of the Board of LivaNova, has begun to assume the responsibilities of interim Chief Executive Officer.

In September, LivaNova announced the current president of its cardiopulmonary business unit.Marco DolciPlan to retire before December 31, 2023.Franco Poretti will serveCardiopulmonary Business DepartmentThe temporary president and the position of vice president of the department in Europe.

October 6,LivaNovaAppointed the former CEO of spinal leader company NuVasive,J. Christopher BarryForNew DirectorFollowing this appointment, the LivaNova Board of Directors will consist of 10 members. (For more details, see "Latest! ECMO Giant's Personnel Changes》）

J. Christopher Barry has over two decades of experience in the medical technology industry. He served as the Chief Executive Officer and Director of NuVasive from 2018 until the company's merger with Globus Medical was completed. Prior to joining NuVasive,J. Christopher BarryFrom January 2015 to October 2018, he served as Senior Vice President of Medtronic and President of the Surgical Innovations division. In addition, he has also worked at Covidien.Held sales and leadership positions for up to 15 years.

# 11 Mindray

At the beginning of 2023, Feng Xuanyun, the former General Manager of Mindray's China Marketing, stepped down from his position.NewMindray's General Manager for China is Zhao Yuxiang.(According toLatest Report on January 29, 2024 from Xuzhou Medical University: The General Manager of Mindray China has changed from Zhao Yuxiang toHuang Pengcheng。）

# 12 Baxter

March 12, 2023Baxter Announces Six Executive Leadership Changes, including:

AppointmentHeather KnightForExecutive VicePresident and Medical IndustryPresident of Products and Therapies;
AppointmentReyz LassouFor Executive Vice President and President of Medical Systems and Technology Business;
Appointment of Alok SoniExecutive Vice President and President of the Pharmaceutical Business;
AppointmentCathy SmithNominated for the Board of Directors, Corporate Director, and Chairman of the Public Policy Committee;
AppointmentPeter WilferChairman of the Board Audit Committee;
AppointmentBrent SchaeferAs the Chief Independent Director.

# 13 Insulet

In 2023, to accelerate the pace of innovation and commercialization, a new type of insulin pump was developed.Insulet Divides Chief Commercial Officer Responsibilities into Two New Leadership Positions。Eric Benjamin, Executive Vice President of Original Innovation and Strategy, has been promoted to Chief Product and Consumer Experience Officer.Mark Field, former Vice President of the Software Engineering Group, serves as the Chief Technology Officer.

# 14 ResMed

April 3, 2023Global Ventilator GiantResMedAnnounced, the company's Chief Administrative Officer and Global General CounselDavid PendavisAbout to retire. Therefore, the current Vice President of Corporate Communications and Investor Relations will be appointed.Amy WakehamAs the Chief Communications and Investment Affairs Officer, he willLead corporate public affairs.

# 15 Recor Medical

The world's first RDN developer approved by the FDARecor Medical, announced the appointmentLara Barghout as the new Chief Executive Officer and President, marking an important step in the company's global commercialization process. Barguet, former executive of Siemens Healthcare and Terumo Corporation, will succeed Andrew Weiss. Since 2013, Weiss has served as the CEO of ReCor Medical, leading the development, clinical trials, and FDA submission of this technology.

# 16 China Resources Medical Devices

February 27, 2023A wholly-owned subsidiary of China Resources Pharmaceutical Commercial GroupCR Medical Devices Announces Six Senior Management Personnel Changes

Cheng Li Bing resigns from the positions of Executive Director, President, and Authorized Representative of the company;
Yu Hai was appointed as the Executive Director and President of the company;
Song Qing Appointed as Corporate Authorized Representative;
Mr. Li Jiacong resigned from his position as a member of the Company's Audit Committee;
Hu Hui resigned from the position of member of the Company's Remuneration Committee;
Fu Tingmei has been appointed as an independent non-executive director of the company, a member of the audit committee, and a member of the remuneration committee.

#17 Silk Road Medical

Chase McHan has joined Silk Road Medical as Chief Executive Officer, succeeding Erica Rogers, who is retiring. McHan previously served as CEO of Apollo Endosurgery, which was acquired by Boston Scientific in April 2023.Acquired for $615 million.

#18 Cordis

Scott Drake, former CEO of Spectranetics, has been appointedChairman of the Executive Board of Cordis。

#19 Orthofix

Orthofix Medical, Inc. made significant personnel adjustments after merging with SeaSpine, dismissing CEO Keith Valentine, CFO John Bostjancic, and Chief Legal Officer Patrick Cline. This decision was made following an internal investigation that found they had engaged in "repeated improper and offensive behavior." Subsequently, Orthofix announced the appointment of...Massimo Carrafiori as the new Chief Executive OfficerCarafiore formerly served as the CEO of LimaCorporate and had been serving as the CEO and President of Orthofix prior to Enovis' acquisition of LimaCorporate in January 2024.

#20 Distalmotion

Swiss company Distalmotion announces appointmentGregg Roch as Chief Executive Officer...to further expand the company's surgical robotics business. Roche previously served as the CEO of Avatera Medical, a soft tissue robotics company, and prior to that, held the position of Global President of Robotics and Technology at Zimmer Biomet.

#21 Shockwave Medical

Intravascular Lithotripsy Technology Manufacturer Shockwave Medical Announces Appointment ofDr. Nick West as Chief Medical Officer CandidateDr. Nick West, former Chief Medical Officer and Vice President of Global Medical Affairs at Abbott Vascular, is expected to assume the position in mid-2024, succeeding Dr. Keith Dawkins.

#22 Biosense Webster

Jasmina BrooksThe woman has been appointed to Biosense Webster, a subsidiary of Johnson & Johnson.The Next PresidentShe will succeed the current president, Michael Bordin, who will soon take on the role of Global Head of Cardiac Recovery at Johnson & Johnson Medical Technologies.

#23 Dexcom

DexcomCompany Announces Appointment of Seasoned Professional in Medical Technology FieldTerry Lauter`, serving as the newly established`Chief Business OfficerPosition.Terry LauterHeld a leadership position at Johnson & Johnson for up to twenty years, with responsibilities covering medical devices, consumer healthcare technology, and the pharmaceuticals field.

#24 iRhythm

iRhythmChief Operating Officer Douglas Devon to Resign, the company stated that this is related to the ongoing "business transformation." Douglas Devon, former Chief Financial Officer of the company, will continue to serve as an executive advisor until July 3, 2024.

#25 Integra Lifesciences

CFO of Integra LifeSciencesCarrie Anderson Leaves the Medical Technology Industry, serving as the Executive Vice President and Chief Financial Officer of Campbell Soup Company.

#26 Shenzhen Lifotronic Technology Co., Ltd.

January 18, 2023, Shenzhen Lifotronic Technology Co., Ltd. announced that the company's director and core technical personnel...Xu YanThe gentleman recently submitted a request to the company due to personal health reasons.Resignation Application。

It is reported that Shenzhen Lifotronic Technology Co., Ltd. is a national high-tech enterprise specializing in high-tech medical devices, driven by both research and development and market demands. The company has launched comprehensive solutions suitable for various application scenarios across its two major product lines: in-vitro diagnostics and therapeutic rehabilitation.

#27 Dirui Industrial Co.,Ltd.

On January 3, 2023, Zhang Dongdong, Vice General Manager of Dirui Industrial Co., Ltd., resigned for personal reasons.Application for Resignation from the Position of Deputy General Manager of the Company；On April 11, Zheng Guoming, Executive General Manager of Dirui Industrial Co., Ltd.,Application for Resignation from the Position of Company Director。Continued to serve as a senior executive in the company after resignation.

Dirui Industrial Co., Ltd. is a leading Chinese manufacturer of medical testing instruments and配套试纸试剂 in China, with product lines covering seven major series: urine analysis, biochemical analysis, hematology analysis, chemiluminescence immunoassay, gynecological secretion analysis, coagulation analysis, and standardized laboratories. The company joined the China Resources Group in 2020.